How to Find an Unrelated Donor Theory & Technology

Similar documents
New trends in donor selection in Europe: "best match" versus haploidentical. Prof Jakob R Passweg

21/05/2018. Continuing Education. Presentation Recording. learn.immucor.com

Documentation of Changes to EFI Standards: v 5.6.1

MATCHMAKER, MATCHMAKER, MAKE ME A MATCH, FIND ME A MISMATCHED TRANSPLANT TO CATCH

Factors Influencing Haematopoietic Progenitor cell transplant outcome Optimising donor selection

HLA Mismatches. Professor Steven GE Marsh. Anthony Nolan Research Institute EBMT Anthony Nolan Research Institute

Role of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT

Support of Unrelated Stem Cell Donor Searches by Donor Center-Initiated HLA Typing of Potentially Matching Donors

Cover Page. The handle holds various files of this Leiden University dissertation.

Histocompatibility Evaluations for HSCT at JHMI. M. Sue Leffell, PhD. Professor of Medicine Laboratory Director

Basel - 6 September J.-M. Tiercy National Reference Laboratory for Histocompatibility (LNRH) University Hospital Geneva

HLA-A * L

Sylwia Mizia, 1 Dorota Dera-Joachimiak, 1 Malgorzata Polak, 1 Katarzyna Koscinska, 1 Mariola Sedzimirska, 1 and Andrzej Lange 1, 2. 1.

Haplo vs Cord vs URD Debate

DEFINITIONS OF HISTOCOMPATIBILITY TYPING TERMS

EBMT2008_1_21:EBMT :06 Pagina 46 * CHAPTER 3. Immunogenetics of allogeneic HSCT * 3.1. The role of HLA in HSCT. J.M.

Title: SECTION 7.0 NZBMDR STANDARDS PROCESS FOR DONOR IDENTIFICATION

The National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient

Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched. unrelated donors

EZER MIZION PROCEDURES FOR TRANSPLANT CENTERS AND COOPERATIVE REGISTRIES

25/10/2017. Clinical Relevance of the HLA System in Blood Transfusion. Outline of talk. Major Histocompatibility Complex

MICA in HSCT. Mannheim,

National Marrow Donor Program HLA-Matching Guidelines for Unrelated Marrow Transplants

Supplementary Appendix

The Human Major Histocompatibility Complex

OPERATIONS AND PATIENT SERVICES USER GUIDE. Procedures for transplant centres and international establishments

Objectives. The need for national registry Beginning of SSCDR SSCDR collaborations Achievements so far Our future goals How can we help

Clinical Relevance of the HLA System in Blood Transfusion. Dr Colin J Brown PhD FRCPath. October 2017

Human Leukocyte Antigens and donor selection

HLA and new technologies. Vicky Van Sandt

The MHC and Transplantation Brendan Clark. Transplant Immunology, St James s University Hospital, Leeds, UK

LEGISLATIVE FRAMEWORKS AND ETHICS OF DONATION. Jeff Szer, Royal Melbourne Hospital, Australia

Completing the CIBMTR Confirmation of HLA Typing Form (Form 2005)

Significance of the MHC

HLA Amino Acid Polymorphisms and Kidney Allograft Survival. Supplemental Digital Content

Strategies for successful donor recruitment

Virtual Crossmatch in Kidney Transplantation

6/19/2012. Who is in the room today? What is your level of understanding of Donor Antigens and Candidate Unacceptables in KPD?

Epitope matching in solid organ transplantation: T-cell epitopes

Related haploidentical donors versus matched unrelated donors

The role of HLA in Allogeneic Hematopoietic Stem Cell Transplantation and Platelet Refractoriness.

16/01/2018. Pre-Transplant Immunogenetic and Immunological assessment for Hematopoietic Stem Cell Transplantation

Pre-Transplant Immunogenetic and Immunological assessment for Hematopoietic Stem Cell Transplantation

D7.1 Report summarising results of survey of EU countries to identify volumes and trends in relation to the import and export of stem cells

D7.1 Report summarising results of survey of EU countries to identify volumes and trends in relation to the import and export of stem cells

An Introduction to Bone Marrow Transplant

MUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University

Impatto clinico nel trapianto allogenico da donatori non familiari dei mismatch al locus HLA-DPB1

Management of platelet refractory patients, why does your patient keep on bleeding? Dr Colin Brown, H&I Dept, NHSBT Colindale

Allele and Haplotype Frequencies of Human Leukocyte Antigen-A, -B, -C, -DRB1, and -DQB1 From Sequence- Based DNA Typing Data in Koreans

Rob Wynn RMCH & University of Manchester, UK. HCT in Children

Calculation Tables. Olerup SSP Kits without Taq Polymeras

Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The impact of HLA matching on unrelated donor hematopoietic stem cell transplantation in Korean children

Calculation Tables. Olerup SSP Kits without Taq Polymeras

Seventy percent of people who are candidates for allogeneic hematopoietic

Samples Available for Recipient Only. Samples Available for Recipient and Donor

HAEMATOPOIETIC STEM CELL TRANSPLANTATION

Chapter 10. Histocompatibility Testing

Significance of the MHC

Samples Available for Recipient and Donor

Samples Available for Recipient Only. Samples Available for Recipient and Donor

About OMICS Group Conferences

FROM STRENGTH TO STRENGTH

Donor and stem cell source selection. TRAINING COURSE E. Baudoux S. Servais

XIV. HLA AND TRANSPLANTATION MEDICINE

Biol Blood Marrow Transplant 17: (2011) Ó 2011 American Society for Blood and Marrow Transplantation

Cord Blood Transplant. E. Gluckman Eurocord ESH-EBMT training course Vienna 2014

BE THE MATCH. The Role of HLA in Finding a Match for Bone Marrow or Peripheral Blood Stem Cell Transplantation

Alternative Donor Sources for Hematopoietic Stem Cell Transplantation

HLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the U.S. Registry

Bone marrow transplantation for PID

Umbilical Cord Blood Transplantation

Biol Blood Marrow Transplant 19 (2013) 221e226

HLA AND KIR GENE POLYMORPHISM IN HEMATOPOIETIC STEM CELL TRANSPLANTATION

Transplantation Immunology Booklet C

CHAPTER 3 LABORATORY PROCEDURES

Effects of age-at-diagnosis and duration of diabetes on GADA and IA-2A positivity

Blood and Marrow Transplant (BMT) for Sickle Cell Disease

Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA Match

Disclosures of: Emanuele Angelucci

The Relationship between Minor Histocompatibility Antigens and Graft Versus Host Disease in Unrelated Peripheral Blood Stem Cell Transplants

BDC Keystone Genetics Type 1 Diabetes. Immunology of diabetes book with Teaching Slides

Available online at , 2(1):27-37

Transplant Booklet D Page 1

Using HLA Typing to Support Patients With Cancer

HISTOCOMPATIBILITY LABORATORIES

Just the FACTS: You can help! Join the NMDP Registry. Vital Statistics

Impact of HLA-Mismatch in Unrelated Donor Hematopoietic Stem Cell Transplantation: A Meta-Analysis

Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017

2017 EFI/DGI Meeting Teaching Session I

OPTN/UNOS Policy Notice Review of HLA Tables (2016)

Medhat Askar, 1 Ronald Sobecks, 2 Yasuo Morishima, 3 Takakazu Kawase, 3 Amy Nowacki, 4 Hideki Makishima, 5 Jaroslaw Maciejewski 5

Dr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION

Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD

NHS BLOOD AND TRANSPLANT KIDNEY OFFERING SCHEME WORKING GROUP ENDORSEMENT OF A NEW NATIONAL KIDNEY OFFERING SCHEME

The Use of HLA /HPA Selected Platelets

Robert B. Colvin, M.D. Department of Pathology Massachusetts General Hospital Harvard Medical School

Plenary paper. Introduction

Transcription:

How to Find an Unrelated Donor Theory & Technology Carlheinz R. Müller Zentrales Knochenmarkspender-Register für die Bundesrepublik Deutschland (ZKRD) Ulm, Germany

How to Find an Unrelated Donor HLA-Basics polymorphism, haplotypes, frequencies Selection Criteria and Supporting Evidence Donor Registries geography, quantity and quality Global Networks EMDIS, BMDW and the future Current Matching Technology The principles behind OptiMatch, HapLogic e.a.

The Most Important MHC Loci for HSCT HLA-A: 21 / 1243 variants (+863) HLA-B: 44 / 1773 variants (+1093) HLA-C: 9 / 884 variants (+681) HLA-DR(B1): 14 / 736 variants (+331) HLA-DQ(B1): 7 / 109 variants (+46) HLA-DP(B1): 6 / 129 variants (+18) serological antigens / ARS protein variants as of July 2011 (increase since March 2005) class II class III class I DP.. DQ.. DR.. B C A

Virtually Unlimited Possibilities alleles genotypes@locus haplotypes phenotypes A 1,243 773,146 1.2 10 3 7.7 10 5 B 1,773 1,572,651 1.1 10 6 6.1 10 11 C 884 391,170 4.9 10 8 1.2 10 17 DRB1 736 271,216 1.8 10 11 1.6 10 22 DQB1 109 5,995 9.8 10 12 4.8 10 25 ARS protein variants as of July 2011

Haplotype Frequency frequ uency 1e-08 1e-06 1e-04 1e-02 1e+01 1e+02 1e+03 1e+04 1e+05 number of haplotypes

Cumulative Haplotype Frequency cumulative frequency 0.0 0.2 0.4 0.6 0.8 1.0 1e+01 1e+02 1e+03 1e+04 1e+05 number of haplotypes

Quiz What would have happened if HLA-A,-B, -C,-DRB1 and -DQB1 were located on three separate chromosomes? What is the probability that two siblings have the same two haplotypes for five chromosomes?

General / HLA-C: DPB1 Basis of Evidence for Our Current Practice (Selection) Flomenberg: Impact of high-resolution matching... (Blood, 2004) Lee: High-resolution... HLA matching (Blood, 2007) Woolfrey: HLA-C antigen mismatch... (BBMT, 2011) Fürst: High-resolution HLA matching... (Blood, 2013) Shaw: HLA-DPB1 matching status... (Blood, 2006) Fleischhauer:... HLA-DPB1 T-cell epitope matching... (BMT, 2014) Pidala: Non-permissive HLA-DPB1 mismatch... (Blood, 2014) Low expression HLA loci: Fernández-Viña: Multiple mm at low expr. loci... (Blood, 2013)

Survival for Early Disease High Resolution HLA-matching in Hematopoietic Stem Cell Transplantation, Fürst e.a., Blood, 2013 100 90 80 10/10 n=674 9/10 n=319 8/10 n=89 p=0.019 p=0.002 70 Surviva al % 60 50 40 30 20 10 0 0 12 24 36 48 60 Months after Transplantation

Survival for Intermediate Disease High Resolution HLA-matching in Hematopoietic Stem Cell Transplantation, Fürst e.a., Blood, 2013 100 90 80 10/10 n=622 9/10 n=272 8/10 n=70 p=0.002 p=0.008 70 Surviva al % 60 50 40 30 20 10 0 0 12 24 36 48 60 Months after Transplantation

Survival for Advanced Disease High Resolution HLA-matching in Hematopoietic Stem Cell Transplantation, Fürst e.a., Blood, 2013 100 90 80 10/10 n=431 9/10 n=196 8/10 n=44 p=0.008 p=0.019 70 Surviva al % 60 50 40 30 20 10 0 0 12 24 36 48 60 Months after Transplantation

Hazard Ratio for Overall Survival High Resolution HLA-matching in Hematopoietic Stem Cell Transplantation, Fürst e.a., Blood, 2013 HLA-match n RR 95% CI p 10/10 1511 1.00 9/10 803 1.26 1.11-1.43 <0.001 8/10 247 1.86 1.51-2.29 <0.001 8/10 versus 9/10 247 1.47 1.19-1.82 <0.001

Hazard Ratio for Overall Survival High Resolution HLA-matching in Hematopoietic Stem Cell Transplantation, Fürst e.a., Blood, 2013 HLA-match n RR 95% CI p 10/10 1511 1.00 9/10 803 1.26 1.11-1.43 <0.001 2 MM HLA-class I+II 67 2.20 1.60-3.03 <0.001 2 MM only HLA-class I 162 1.68 1.27-2.22 <0.001 2 MM only HLA-class II 18 1.83 1.04-3.22 0.036

Impact of Single Locus Mismatch High-resolution donor-recipient HLA-matching contributes to the success of unrelated donor marrow transplantation, Lee e.a. Blood 2007

What is Quite Well Established Matching HLA-A,-B,-C and DRB1 is important! Mismatching is bad. More mismatching is worse. Younger donors are better. Don t wait too long for a better match. Most other criteria are new, not unequivocally validated and/or explicitly controversial.

Common Practices and New Trends Ignore mismatches outside the ARS (antigen recognition site = exon 2+3 for class I and exon 2 for class II loci) Matching or permissible mismatching for HLA-DPB1 Accept DQB1-MM on 8/8 donors. Prefer male donors (in the malignant setting) or gender-identical donors (non-malignant disease). Accept C-allele variants first if necessary. Prefer donors with identical CMV-status.

Age Distribution of German Donors At Collection Age Distribution of Donors at Collection 300 250 2014 Male 2014 Female 2013 Male 2013 Female 200 Num mber 150 100 50 0 20 25 30 35 40 45 50 55 60 Age

Limits of knowledge KIR? If so, which model to use and when? (haplotype, ligand, missing ligand,...) Weighing criteria is difficult. Which locus should I mismatch? Is some allele mm better than an antigen mismatch What is more important: age, gender, CMV status?

ZKRD Donor Numbers ZKRD Donor Numbers 6.000.000 5.000.000 Total HLA A,B,DRB1 typed HLA DRB1 high res. 4.000.000 Num mber 3.000.000 2.000.000 1.000.000 0 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014 Year

Donor Numbers Worldwide Donor Numbers Worldwide (according to BMDW) 25.000.000 20.000.000 Num mber 15.000.000 10.000.000 5.000.000 0 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 Year Total HLA A,B,DRB1 typed

data provided by Joris&Foeken, WMDA Office, Leiden NL

data provided by Joris&Foeken, WMDA Office, Leiden NL

ZKRD Donor Numbers ZKRD Donor Numbers 3.500.000 3.000.000 HLA A,B,DRB1 high res. HLA A,B,C,DRB1 high res. HLA A,B,C,DRB1,DQB1 high res. 2.500.000 Num mber 2.000.000 1.500.000 1.000.000 500.000 0 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Year

BMDW FIRST EDITION (Bone Marrow Donors Worldwide) Initiated by Professor Jon van Rood in Leiden in 1988 Operated by the Dutch Registry Europdonor HLA phenotype data from 75 registries with 25m donors in 54 countries 50 cord blood banks and registries in 34 countries with 634k units continuously updated online at http://www.bmdw.org

The Global EMDIS B2B-Network (European Marrow Donor Information System) DC DC DC DC ZKRD DC DC DC DC DC Simple Principles DC DC DC DC DC DC IBMDR DC DC DC DC DC DC FGM DC DC DC in a Complex Reality

Mission of WMDA The World Marrow Donor Association (WMDA) is working towards the goal that high-quality and secure haematopoietic stem cell products are available for all patients worldwide while maintaining the health and welfare of the stem cell donors. https://wmda.info mail@wmda.info

World Marrow Donor Association (WMDA) Network of more than 70 registries and cord blood banks from over 40 countries active in the international field of HSCT Five Working Groups (Registries, Cord Blood, Quality and Regulation, Medical, IT) Six Board Committees (Standard, Accreditation, S(P)EAR, Finance, Nomination, Conference Programme) International Donor Registry Conference (last London 2014; next Singapore 2016)

Current Challenges in Donor Search Donor searches with few potential matches: Accepting mismatches early may be crucial. Prospects not be as bad as they look. Donor searches with many potential matches: It is difficult to pick the most promising donors out of a huge set. Chances may be still be pretty bad due to incomplete or low resolution typing, rare alleles or rare associations.

Do not create unnecessary concern

Current Challenges in Donor Search Donor searches with few potential matches: Accepting mismatches early may be crucial. Prospects not be as bad as they look. Donor searches with many potential matches: It is difficult to pick the most promising donors out of a huge set. Chances may be still be pretty bad due to incomplete or low resolution typing, rare alleles or rare associations.

Do not create false hope

4 2x10 5 2x10 11 5x10 17

You need good tools to become stronger!

Virtually Unlimited Possibilities alleles haplotypes A 1,243 1.2 10 3 B 1,773 1.1 10 6 C 884 4.9 10 8 DRB1 736 1.8 10 11 DQB1 109 9.8 10 12 but only 10 5 relevant haplotypes in the German population So just 1 in 10 8 is really present!

Donor #1 alleles/genotypes ARS-group probabilities 4-digits A*02:CVYA,24:ENHC 5*46=230 5*34=170 97% B*35:EKNR,14:BH 14*2=28 10*2=20 99% C*04:EKPB,08:EKPD 19*4=76 16*4=64 99% DRB1*01:02,14:01 1*1=1 1*1=1 100% DQB1*05:01,05:03 1*1=1 1*1=1 100% genotypen 489440 217600 97% diplotypes 1.1024e-06 02:01-35:01-04:01-14:01-05:03 24:02-14:02-08:02-01:02-05:01 5.7291e-07 02:01-14:02-08:02-01:02-05:01 24:02-35:01-04:01-14:01-05:03 4.4895e-08 02:17-35:01-04:01-14:01-05:03 24:02-14:02-08:02-01:02-05:01 ARS-genotypes 1.6753e-06 4.4895e-08 02:01P,24:02P-14:02P,35:01P-04:01P,08:02P-01:02P,14:01P-05:01P,05:03P 02:17P,24:02P-14:02P,35:01P-04:01P,08:02P-01:02P,14:01P-05:01P,05:03P

Donor #2 alleles/genotypes ARS-group probabilities 4-digits A2s,24s 194*99=19206 169*82=13858 87% B65s,35s 16*99=1584 16*91=1456 81% Cw4,8 48*29=1392 42*26=1092 99% DRB1*01:02,14:BCAD 2*1=2 1*1=1 100% DQB1*05:RV 4*(4+1)/2=10 4*(4+1)/2=10 99% genotypes 8*10^11 2*10^11 73% diplotypes 1.1024e-06 02:01-35:01-04:01-14:01-05:03 24:02-14:02-08:02-01:02-05:01 5.7291e-07 02:01-14:02-08:02-01:02-05:01 24:02-35:01-04:01-14:01-05:03 4.233e-07 02:01-14:02-08:02-01:02-05:01 24:02-35:01-04:01-14:54-05:03 2.2055e-07 02:01-35:01-04:01-14:54-05:03 24:02-14:02-08:02-01:02-05:01 2.0273e-07 02:01-14:02-08:02-01:02-05:01 24:02-35:03-04:01-14:01-05:03 1.1743e-07 02:01-14:02-08:02-01:02-05:01 24:02-35:08-04:01-14:01-05:03 6.8989e-08 02:05-14:02-08:02-01:02-05:01 24:02-35:01-04:01-14:01-05:03... total 106 ARS-genotypes 2.3192e-06 02:01P,24:02P-14:02P,35:01P-04:01P,08:02P-01:02P,14:01P-05:01P,05:03P... total 76

Donor #3 alleles/genotypes ARS-group probabilities 4-digits A2s,24s 194*99=19206 169*82=13858 90% B65s,35s 16*99=1584 16*91=1456 68% Cw 808*(808+1)/2=326836 757*(757+1)/2=286903 77% DRB1*01:02,14:JFA 1*6=6 1*6=6 99% DQB1 581*(581+1)/2=169071 218*(218+1)/2=23871 99% genotypes 9*10^18 5*10^17 56% diplotypes 1.1024e-06 02:01-35:01-04:01-14:01-05:03 24:02-14:02-08:02-01:02-05:01 5.7291e-07 02:01-14:02-08:02-01:02-05:01 24:02-35:01-04:01-14:01-05:03 2.3207e-07 02:01-14:02-08:02-01:02-05:01 24:02-35:03-12:03-14:01-05:03 2.0273e-07 02:01-14:02-08:02-01:02-05:01 24:02-35:03-04:01-14:01-05:03 1.5522e-07 02:01-35:03-12:03-14:01-05:03 24:02-14:02-08:02-01:02-05:01 1.1743e-07 02:01-14:02-08:02-01:02-05:01 24:02-35:08-04:01-14:01-05:03 6.8989e-08 02:05-14:02-08:02-01:02-05:01 24:02-35:01-04:01-14:01-05:03... total 332 ARS-genotypes 1.6753e-06 02:01P,24:02P-14:02P,35:01P-04:01P,08:02P-01:02P,14:01P-05:01P,05:03P... total 234

4 2x10 5 2x10 11 5x10 17

reduces the number of possibilities using HLAhaplotype frequencies 1 2 76 234

indicates the probability of allele identity

the shift from the haystack to the silver tray.

What You Need to Search for Unrelated Donors expertise in HLA and population diversity a lot of background knowledge adequate infrastructure link to / accreditation by a registry

Matching resolution and donor identification rates in Germany f patients with donors percentage of 50 60 70 80 90 100 0 10 20 30 40 HLA A, B, C, DRB1, DQB1 high res. matching 0 mismatch 1 mismatch 2 mismatches 1.000 10.000 100.000 1.000.000 10.000.000 100.000.000 number of donors in the registr y

With all enthusiasm for novel cell- and gene-based medicines: Take into account the donors rights and needs! They are not like that:

Thanks to all volunteer donors worldwide for their dedication all colleagues in our partner transplant centres, search units and donor centres for their excellent cooperation IMGT-HLA database: Prof. Steven G. E. Marsh and James Robinson http://hla.alleles.org/wmda/index.html WMDA: Lydia Foeken and Monique Jöris BMDW: Jon van Rood, Machteld Oudshoorn and others EMDIS too many names... and the -Team: Werner Bochtler, Hans-Peter Eberhard, Ulrike and Markus Beth, Heiko Hummler, Andrea Timm and Hans-Georg Rist

We hope to see you some time in Ulm

In theory there is no difference between theory and practice. In practice, however, there is. Yogi Berra